Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Decline in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 8,448 shares, a decline of 83.0% from the July 15th total of 49,784 shares. Based on an average daily volume of 31,236 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s shares are sold short.

Sonoma Pharmaceuticals Stock Down 2.2%

Shares of SNOA traded down $0.03 during trading hours on Thursday, reaching $1.34. The company’s stock had a trading volume of 155,260 shares, compared to its average volume of 206,391. The company has a 50 day moving average of $1.19 and a two-hundred day moving average of $1.83. The firm has a market cap of $6.42 million, a price-to-earnings ratio of -1.10 and a beta of 1.28. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.32. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 26.32%. The firm had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Sonoma Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Sonoma Pharmaceuticals presently has a consensus rating of “Sell”.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC grew its position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the period. DRW Securities LLC owned about 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent quarter. 1.95% of the stock is owned by hedge funds and other institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.